¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"late phase reaction"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • phase difference
    À§»óÂ÷
  • phase display
    À§»óÇ¥½Ã
  • phase encoding gradient
    À§»óºÎȣȭ±â¿ï±â
  • phase encoding step
    À§»óºÎȣȭ´Ü°è
  • phase image
    À§»ó¿µ»ó
  • phase offset multiplanar imaging
    À§»ó¿ÀÇÁ¼Â´Ù¸é¿µ»ó
  • phase ratio
    »óºñ
  • phase reversal
    À§»ó¹ÝÀü
  • phase rule
    »óÀǹýÄ¢, »ó±ÔÄ¢
  • phase shift
    À§»óº¯À§, À§»óÀ̵¿
  • phase shift artifact
    À§»óÀ̵¿Àΰø¹°
  • phase shift effect
    À§»óº¯À§È¿°ú
  • phase transition
    À§»óÀüÀÌ
  • phase wraparound artifact
    À§»óµÑ·¯°ãħÀΰø¹°
  • phase-contrast microscope
    À§»óÂ÷Çö¹Ì°æ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • isometric contraction phase
    µîô¼º¼öÃà±â
  • isovolumetric contraction phase
    µî¿ëÀû¼º¼öÃà±â
  • phase image
    À§»ó¿µ»ó
  • phase offset multiplannar imaging
    À§»ó¿ÀÇÁ¼Â´Ù¸é¿µ»ó
  • lactiferous phase
    ¼öÀ¯±â
  • leptotene phase
    °¡´Â¼¶À¯±â
  • logarithmic phase
    ´ë¼öÁõ½Ä±â
  • luteal phase
    Ȳü±â
  • lysogenic phase
    ¿ë¿ø±â
  • manic phase
    Á¶Áõ±â, µé¶ä±â
  • menstrual phase
    ¿ù°æ±â
  • mitosis phase
    À¯»çºÐ¿­±â
  • modulation phase
    º¯Á¶À§»ó
  • phase-contrast microscope
    À§»óÂ÷Çö¹Ì°æ
  • negative phase
    À½¼º±â, À½¼º»ó
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • phase evolution of fat suppression
    À§»ó ¼±È¸ Áö¹æ ¾ïÁ¦
  • phase frequency swap
    À§»ó Á֯ļö ±³È¯
  • phase image
    À§»ó ¿µ»ó
  • phase mismapping
    À§»ó ¿ÀÁöµµÀÛ¼º
  • phase of cornification
    °¢Áú±â
  • phase of decline
    °¨Åð±â, °¨¼Ò±â
  • phase of desquamation
    ¹Ú¸®±â
  • phase of incornification
    ºñ°¢Áú±â
  • phase of life problem
    ÀλýÁÖ±âÀÇ ¹®Á¦
  • phase of meditation
    Àẹ±â°£(íÖÜÑÑ¢Êà).
  • phase of rapid filling
    ±Þ¼ÓÃæ¸¸±â(ÐááÜ õöØ»Ðï).
  • phase of relaxation
    À̿ϱâ(ì¬èÐÐï).
  • phase of shortening
    ´ÜÃà±â(Ó­õêÑ¢).
  • phase offset multiplannar (POMP) imaging
    À§»ó ¿ÀÇÁ¼Â ´Ù¸é ¿µ»ó
  • phase plate
    À§»óÆÇ(êÈßÓ÷ù).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • estrogen phase
    ¿¡½ºÆ®·Î°Õ±â(Ñ¢).
  • estrogen phase
    ¿¡½ºÆ®·Î°Õ±â.
  • excitement phase
    ÈïºÐ±â
  • expiratory phase
    È£½Ä»ó(û¼ãÓßÓ).
  • expiratory phase time
    È£±â»ó ½Ã°£.
  • explosive phase
    Æø¹ß±â(̰ËÑË»).
  • exponential growth phase
    Áö¼öÁõ½Ä±â(ÊÙÌ¡ËàË»).
  • exponential phase
    ´ë¼öÁõ½Ä±â, Áö¼öÁõ½Ä±â
  • exponential phase of growth
    ´ë¼öÁõ½Ä±â, °¡¼Ó¼ºÀå±â.
  • filling phase
    Ãæ¸¸±â(õöػѢ).
  • flagellar phase variation
    Æí¸ðÀ§»óº¯ÀÌ
  • follicle phase
    ³­Æ÷±â(Õ°øàÑ¢).
  • follicular phase
    ³­Æ÷±â(Õ°øàÑ¢).
  • follicular phase
    ³­Æ÷±â
  • full erection phase
    ¿ÏÀü¹ß±â±â
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • chain reaction
    ¿¬¼â¹ÝÀÀ(ææáðÚãëë)
  • chemical reaction
    È­ÇйÝÀÀ(ûùùÊÚãëë)
  • complement binding reaction
    º¸Ã¼°íÁ¤ ¹ÝÀÀ(ÜÍô÷ͳïÒÚãëë)
  • concerted reaction
    Çùµ¿¹ÝÀÀ(úðÔÒÚãëë)
  • cross-reaction
    ±³Â÷¹ÝÀÀ(Îßó©Úãëë)
  • cyanogen bromide reaction
    ºê·ÒÈ­ ½Ã¾È ¹ÝÀÀ(Úãëë)
  • cycloaddition reaction
    °í¸® ÷°¡¹ÝÀÀÈ­(ôÕÊ¥Úãëëûù)
  • dark reaction
    ¾Ï¹ÝÀÀ(äÞÚãëë)
  • diffusion-limited reaction
    È®»êÁ¦ÇÑ ¹ÝÀÀ(üªß¤ð¤ùÚÚãëë)
  • diphenylamine reaction
    ÀÌ(ì£)Æä´Ò¾Æ¹Î ¹ÝÀÀ(Úãëë)
  • Dische reaction
    µð½¬ ¹ÝÀÀ(Úãëë) (ÔÒ) diphenyulamine reaction
  • displacement reaction
    ´ëÄ¡ ¹ÝÀÀ(ÓÛöÇÚãëë)
  • disproportionation reaction
    ºÒ±Õµî¹ÝÀÀ(ÝÕгÔõÚãëë)
  • DNA polymerase chain reaction
    DNA Æú¸®¸Ó·¹À̽º ¿¬¼â ¹ÝÀÀ(ææáðÚãëë) (ÔÒ) polymerase chain reaction
  • downhill reaction
    ³»¸®¸· ¹ÝÀÀ(Úãëë) (ÔÒ) exergonic reaction
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
WR Wassermann reaction; water retention; weakly reactive; weak response; whole response; wiping reactio...
AMI Acute Myocardial Infarction
  - Complications(Cx)
    1. Early ...
LAE   1) Late Asthmatic Effect
  2) Left Atrial Enlargement
LAM laminectomy; laminin; late ambulatory monitoring; Latin American male; left anterior measurement; le...
LC Laennec cirrhosis; Langerhans cell; late clamped; large chromophobe; lecithin cholesterol acyltransf...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
VLP Ventricular late potentials
VLA Very Late Activation
VLA Very Late Activation Antigen
VLA Very Late Antigen
VLA-4 Very Late Antigen-4
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • prodromal vasoconstriction phase
    Àü±¸¼º Ç÷°ü ¼öÃà±â
  • proliferation phase
    Áõ½Ä±â
  • respiratory ordered phase encoding
    È£Èí ¼øÀ§ »ó ºÎȣȭ
  • rising phase
    »ó½Â±â
  • S phase
    S ±â
    Á¤Áö±â, °íÁ¤»ó. ¼¼±Õ ¹è¾ç¿¡ À־ ¼¼±ÕÀÇ Áõ½ÄÀÌ ¼­¼­È÷ ÁÙ¾îµé¾î ¼¼±Õ ¼ö°¡ °ÅÀÇ ÀÏÁ¤ÇÑ ¼ö·Î º¸ÀüµÇ´Â ½Ã±â.
  • sleep phase advance
    ¼ö¸é À§»ó ÀüÁø
  • spin phase effect
    ½ºÇÉ À§»ó È¿°ú
  • stationary phase of growth
    Áõ½Ä Á¤Áö±â
  • symbiotic phase
    °ø»ý±â
  • unequal phase
    ºñ´ëαâ
  • yeast phase
    È¿¸ð»ó
  • Abderhalden's reaction
    ¾Ðµ¥¸£ÇÒµ§ ¹ÝÀÀ
    ÀÌÁ¾ ´Ü¹éÁúÀÌ Ç÷¾× Áß¿¡ ħÀÔÇϸé, »ýü´Â À̰ÍÀ» ºÐÇØÇÏ´Â È¿¼Ò¸¦ »ý»êÇÔÀ¸·Î½á ÀÀ´äÇÑ´Ù´Â ±¸ °¡¼³¿¡ ±âÃÊÇÑ Ç÷û ¹ÝÀÀÀÌ´Ù. ÀÌ·¯ÇÑ ¹æ¾î È¿¼Ò´Â
  • accelerated reaction
    ÃËÁø ¹ÝÀÀ, °¡¼Ó ¹ÝÀÀ
    º¸Åë ¶§º¸´Ù ´Ü ½Ã°£ ³»¿¡ ÀϾ´Â ¹ÝÀÀ.
  • acute hemolytic transfusion reaction
    ±Þ¼º ¿ëÇ÷¼º ¼öÇ÷ ¹ÝÀÀ
  • acute situational stress reaction
    ±Þ¼º »óȲ¼º ½ºÆ®·¹½º ¹ÝÀÀ
    ±ØµµÀÇ È¯°æÀû ½ºÆ®·¹½º¿¡ ´ëÇÑ ÀϽÃÀûÀÎ ¹ÝÀÀÀ¸·Î ±âÃÊÀûÀÎ Á¤½Å Àå¾Ö°¡ ¾ø´Â °³Àο¡°Ô ³ªÅ¸³­´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
phase, resting More appropriately called interphase. The interval in the cell cycle between two cell divisions when the individual chromosomes cannot be distinguished, interphase was once thought to be the resting phase but it is far from a time of rest for the cell. It is the time when DNA is replicated in the cell nucleus.
(12 Dec 1998)
phase rule An expression of the relationships existing between systems in equilibrium: P + V = C + 2, where P is the number of phases, V the variance or degrees of freedom, and C the number of components; it also follows that the variance is, V = C + 2 -P. For H2O at its triple point, V = 1 + 2 -3 = 0, i.e., both temperature and pressure are fixed.
Synonym: Gibb's phase rule.
(05 Mar 2000)
phase separation <chemistry> The separation of fluid phases that contain different concentrations of common components.
Occurs with partially miscible solvents used in many biochemical separation methods. Also temperature dependent phase separation occurs with some detergent solutions. With reference to membranes means the segregation of lipid components into domains that have different chemical composition.
(31 Dec 1997)
phase shift <microscopy> A change in the phase relationship between two alternating quantities of the same frequency.
(05 Aug 1998)
phase variation <microbiology> Alteration in the expression of surface antigens by bacteria.
For example: Salmonella can express either of two forms of flagellin, H1 and H2, that are coded by different genes. Control of which form is expressed is brought about by inversion of the promoter for the H2 gene, which if functional (noninverted) is associated with the expression of H2 and the production of a repressor of the H1 gene.
Inversion occurs about every 1000 bacterial divisions and is under the control of another gene, hin, that is within the invertable sequence.
(31 Dec 1997)
chronic phase Refers to the early stages of chronic myelogenous leukaemia. The number of immature, abnormal white blood cells in the bone marrow and blood is higher than normal, but lower than in the accelerated or blast phase.
(12 Dec 1998)
microscopy, phase-contrast A form of interference microscopy in which variations of the refracting index in the object are converted into variations of intensity in the image. This is achieved by the action of a phase plate.
(12 Dec 1998)
clinical trial, phase I A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on a small number of healthy persons and conducted over the period of about a year in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase II A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on several hundred volunteers, including a limited number of patients, and conducted over a period of about two years in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase III A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques after phase II trials. A large enough group of patients is studied and closely monitored by physicians for adverse response to long-term exposure, over a period of about three years in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale after clinical trials, phases I, II, and III. These studies, conducted in the united states or a foreign country, often garner additional data about the safety and efficacy of a product.
(12 Dec 1998)
clinical trials, phase I Studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase II Studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase III Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á